Business Wire | May 26, 2021 07:00AM EDT

Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference

May 26, 2021

DURHAM, N.C.--(BUSINESS WIRE)--May 26, 2021--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS(r) genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and co-founder, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference being held from June 1-4, 2021.

Details for the fireside chat are below:

Jefferies Virtual Healthcare ConferenceDate: Wednesday, June 2, 2021 Time: 1:30 PM ET

A live webcast of the fireside chat will be accessible on the Company's website www.precisionbiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS(r) genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005350/en/

CONTACT: Investor Contact: Alex Kelly Interim Chief Financial Officer Alex.Kelly@precisionbiosciences.com

CONTACT: Media Contact: Maurissa Messier Senior Director, Corporate Communications Maurissa.Messier@precisionbiosciences.com